LEADER 02277nam 2200349 n 450 001 9910765743003321 005 20230223220639.0 010 $a3-03842-796-9 035 $a(CKB)5400000000000211 035 $a(NjHacI)995400000000000211 035 $a(EXLCZ)995400000000000211 100 $a20230223d2018 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aBiology and Treatment of Myeloid Leukaemias /$fedited by Geoffrey Brown and Ewa Marcinkowska 210 1$aBasel, Switzerland :$cMDPI,$d2018. 215 $a1 online resource (vi, 190 pages) 330 $aThere has been an observed decrease in the global mortality from cancer, mostly atributable to improved, particularly early, detection and prevention. For many carcinomas and leukaemias in adults, once the disease has reached a certain stage there are no therapies that are able to erradicate the cancer cells and cure patients. There has been progress in the treatment of acute myeloid leukaemia (AML) and remissions are achievable; however, the presence of chemoresistent blast cells leads to most patients relapsing, and relapse is difficult to treat and thus patients die due to their disease. Targeting these resistent cells and the leukaemia stem cells, which sustain the leukaemia, is crucial for an effective therapy for AML. Moreover, an increasing number of diverse mutations have been described in AML cells that disrupt the ability of these cells to undergo differentiation. The use of pro-differentiating agents to drive the blast cells to mature, and subsequently undergo apoptosis, provides another approach to therapy. Differentiation therapy, using all-trans retinoic acid (ATRA), an inducer of granulocyte differentiation, has been highly successful in the case of acute promyeloicytic leukaemia, a sub-type of AML, turning this disease into a curable malignancy. 606 $aCarcinogens 615 0$aCarcinogens. 676 $a616.994071 702 $aMarcinkowska$b Ewa 702 $aBrown$b Geoffrey 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910765743003321 996 $aBiology and Treatment of Myeloid Leukaemias$93652641 997 $aUNINA